Paper - WANFANG MED ONLINE

You Position: Home > Paper

Nuclear medical molecular imaging of tumor angiogenesis: current status and future prospects

( views:69, downloads:12 )

Author:: No author available

Journal Title:: Chinese Medical Journal

Issue:: 14

DOI:: 10.3760/cma.j.issn.0366-6999.20122591

Key Word:: molecular imaging;nuclear medicine;angiogenesis

Abstract： Objective To review the current status and progress on nuclear medical molecular imaging of angiogenesis.Data sources A literature search was performed in Medline and PubMed published in English up to May 31,2012.The search terms were molecular imaging,nuclear medicine and angiogenesis.Study selection Articles studying molecular imaging of angiogenesis using radionuclide were selected and reviewed.Results Molecular imaging has been used for studying angiogenesis by targeting integrin αVβ3,VEGFNEGFR,and matrix metalloproteinases (MMPs) with radionuclide-labeled tracers.The technology has been shown to be able to assess the angiogenesis status and/or predict the efficacy of anti-angiogenic therapy.Future directions of the research on the molecular imaging of angiogenesis include development of new tracers with better tumor targeting efficacy,desirable pharmacokinetics,and easy translation to clinical applications.Conclusion Advances in molecular imaging of angiogenesis using radioculcide will make the technology a valuable tool for personalized anti-angiogenesis treatment.

Reference

[1]Passariello R,Gori B,Fraioli F,etc.Whole-Tumor Perfusion CT in Patients with Advanced Lung Adenocarcinoma Treated with Conventional and Antiangiogenetic Chemotherapy: Initial Experience.[J].2011,259(2).
[2]J, Folkman.Tumor angiogenesis: therapeutic implications.[J].1971,285(21).
[3]Saha A,Ellison D,Thomas GJ,etc.High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6.[J].2010,222(1).
[4]Bach-Gansmo T,Skretting A,Bogsrud TV.Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and (99m)Tc-labelled NC100692.[J].2008,28(4).
[5]Zee,Y.-K.,O'Connor,J.P.B.,Parker,G.J.M.,etc.Imaging angiogenesis of genitourinary tumors[J].2010,7(2).
[6]Paladini L,Botrel TE,Clark O,etc.Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis.[J].2011,74(1).
[7]W. Barry Edwards,Yunpeng Ye,Richard Laforest,etc.Multimodal Imaging of Integrin Receptor-Positive Tumors by Bioluminescence, Fluorescence, Gamma Scintigraphy, and Single-Photon Emission Computed Tomography Using a Cyclic RGD Peptide Labeled with a Near-Infrared Fluorescent Dye and a Radionuclide[J].2009,8(2).
[8]Ramanathan RK,Kane P,Rajasenan KK,etc.A Phase I/II Study of Capecitabine Given on a Week on/Week off Schedule Combined With Bevacizumab and Oxaliplatin for Patients With Untreated Advanced Colorectal Cancer.[J].2011,10(2).
[9]Kruijtzer JA,Corstens FH,Soede AC,etc.Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides.[J].2007,34(2).
[10]Ebbinghaus C,Scheuermann J,Neri D,etc.Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis.[J].2004,10(13).
[11]Chen X,Khankaldyyan V,Conti PS,etc.Pegylated Arg-Gly-Asp Peptide: 64Cu Labeling and PET Imaging of Brain Tumor {alpha}v{beta}3-Integrin Expression.[J].2004,45(10).
[12]Waibel R,Birchler MT,Goerres GW,etc.Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment.[J].2007,136(4).
[13]De Zutter A,Depicker A,Goethals I,etc.Tumor perfusion using first-pass F-18 FDG PET images.[J].2012,37(2).
[14]Ergun S,vom Dorp F,Rubben H,etc.Matrix metalloproteinases and their clinical relevance in urinary bladder cancer.[J].2011,8(5).
[15]Cho G,Choi N,Hong KS,etc.The use of the fusion protein RGD-HSA-TIMP2 as a tumor targeting imaging probe for SPECT and PET.[J].2011,32(29).
[16]Chen K,Wang H,Cai W,etc.Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots.[J].2008,35(12).
[17]Jehning BT,Claffey K,Backer MV,etc.Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes.[J].2007,13(4).
[18]David A, Mankoff.A definition of molecular imaging.[J].2007,48(6).
[19]Clevert DA.Vascular targeting tumor therapy: Non-invasive contrast enhanced ultrasound for quantitative assessment of tumor microcirculation.[J].2010,9(10).
[20]Baity WL,Mock BH,Sledge GW,etc.Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-((4-(6-fluorohex-1-ynyl)phenyl)sulfonylamino)-3-methylbutyric acid ((11)C)methyl ester.[J].2003,30(7).
[21]Guo, Z.,Ge, Q.,Jin, G.,etc.Preparation and characterization of RGD tumour-homing-peptide-modified plasminogen K5[J].2010,57(Pt.1).
[22]Cuthbertson A,Ricketts SA,Morrison MS,etc.Use of a Novel Arg-Gly-Asp Radioligand, 18F-AH111585, to Determine Changes in Tumor Vascularity After Antitumor Therapy.[J].2009,50(1).
[23]Sorensen AG,Jain RK,Batchelor TT,etc.Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas.[J].2008,21(6).
[24]Paul K Marsden,Melvyn Myers,Dimitris Visvikis,etc.Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials.[J].2012,22(7).
[25]Cohen PS,Aboagye EO,Miller M,etc.Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.[J].2008,49(6).
[26]Lazzari Agli L,Tassinari D,Carloni F,etc.Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.[J].2011,80(5).
[27]Eder M,Haberkorn U,Backer JM,etc.ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for (68Ga)PET imaging of VEGF receptors in angiogenic vasculature.[J].2010,37(4).
[28]Jeong JM,Hong MK,Chang YS,etc.Preparation of a Promising Angiogenesis PET Imaging Agent: 68Ga-Labeled c(RGDyK)-Isothiocyanatobenzyl-1,4,7-Triazacyclononane-1,4,7-Triacetic Acid and Feasibility Studies in Mice.[J].2008,49(5).
[29]Lee,C.-M.,Kim,E.-M.,Cheong,S.-J.,etc.Targeted molecular imaging of VEGF receptors overexpressed in ischemic microvasculature using chitosan-DC101 conjugates[J].2010,92A(4).
[30]Lear R,Edwards C,Black A,etc.99mTc-NC100692--a tracer for imaging vitronectin receptors associated with angiogenesis: a preclinical investigation.[J].2008,35(3).
[31]del Pilar Camacho Leal M,Di Stefano P,Defilippi P,etc.Integrin signalling adaptors: not only figurants in the cancer story.[J].2010,10(12).
[32]Nagengast WB,de Korte MA,Oude Munnink TH,etc.89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.[J].2010,51(5).
[33]Pauliina Luoto,Tiina Ujula,Merja Huttunen.Matrix Metalloproteinase 9 Targeting Peptides: Syntheses, ~(68)Ga-labeling, and Preliminary Evaluation in a Rat Melanoma Xenograft Model[J].2010,21(9).
[34]Mulder NH,van-Dongen GA,de-Jong JR,etc.In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.[J].2007,48(8).
[35]Desgrosellier JS,Cheresh DA.Integrins in cancer: biological implications and therapeutic opportunities.[J].2010,10(1).
[36]Longo R,Gasparini G.Anti-VEGF therapy: the search for clinical biomarkers.[J].2008,8(3).
[37]Li WP,Anderson CJ,Achilefu S,etc.In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models[J].2006,33(2).
[38]Haijuan Gao,Sudipta Chakraborty,Shuang Liu,etc.~(99m)Tc-Labeled Cyclic RGD Peptides for Noninvasive Monitoring of Tumor Integrin α_vβ_3 Expression[J].2011,10(5).
[39]Richard C, Bates.The alphaVbeta6 integrin as a novel molecular target for colorectal cancer.[J].2005,1(6).
[40]Weis SM,Cheresh DA.Tumor angiogenesis: molecular pathways and therapeutic targets.[J].2011,17(11).
[41]Shuang, Liu.Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency.[J].2009,20(12).
[42]Paudyal B,Paudyal P,Oriuchi N,etc.Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.[J].2011,102(1).
[43]Birchler MT,Milisavlijevic D,Pfaltz M,etc.Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors.[J].2003,113(7).
[44]auf dem Keller U,Bellac CL,Li Y,etc.Novel matrix metalloproteinase inhibitor (18F)marimastat-aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer.[J].2010,70(19).
[45]Foidart JM,Slegers G,Oltenfreiter R,etc.In vitro and in vivo evaluation of [I-123]-VEGF(165) as a potential tumor marker[J].2005,32(5).
[46]Axelsson R,McParland BJ,Bach Gansmo T,etc.An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692.[J].2010,51(1).
[47]Cao Q,Mohamedali KA,Chen K,etc.PET of vascular endothelial growth factor receptor expression.[J].2006,47(12).